CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The upcoming CCTG NE2 (STOPNET) trial was presented at the 25th Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting that was held in Aotearoa New Zealand from November 13 – 16.
Please be aware of the permanent trial closure of the EORTC-led CE5 trial: Primary Chemotherapy with Temozolomide vs. Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.
The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
Results from a phase III international study (IND.227) were recently published in The Lancet and evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy. Researchers conclude that as a first-line treatment for patients with unresectable advanced or metastatic pleural mesothelioma, pembrolizumab plus platinum-pemetrexed chemotherapy represents a new treatment option for patients.
